NXGL (NexGel) Cash-to-Debt : 0.33 (As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NexGel Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. NexGel's cash to debt ratio for the quarter that ended in Sep. 2024 was 0.33.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, NexGel couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for NexGel's Cash-to-Debt or its related term are showing as below:

NXGL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03 Med: 0.76 Max: 3.49
Current: 0.33

During the past 8 years, NexGel's highest Cash to Debt Ratio was 3.49. The lowest was 0.03. And the median was 0.76.

NXGL's Cash-to-Debt is ranked worse than
77.76% of 859 companies
in the Medical Devices & Instruments industry
Industry Median: 1.65 vs NXGL: 0.33

NexGel Cash-to-Debt Historical Data

The historical data trend for NexGel's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

NexGel Cash-to-Debt Chart

NexGel Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.29

0.03

3.13

3.17

0.97

NexGel Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															1.38	0.97	0.79	0.36	0.33

Competitive Comparison of NexGel's Cash-to-Debt

For the Medical Instruments & Supplies subindustry, NexGel's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NexGel's Cash-to-Debt Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NexGel's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where NexGel's Cash-to-Debt falls into.

NexGel Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

NexGel's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.7	/	(0.558	+	2.24)
	=	0.96

NexGel's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.059	/	(0.72	+	2.538)
	=	0.33

NexGel (NAS:NXGL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

NexGel Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of NexGel's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

NexGel Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NexGel Inc (NAS:NXGL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

2150 Cabot Boulevard West, Suite B, Langhorne, PA, USA, 19047

Website

https://www.nexgel.com

NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies.

Executives

Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Drapczuk Adam E Iii	officer: Chief Financial Officer	6 OAKMONT TERRACE, EAST WINDSOR NJ 08520
Steven Mark Glassman	director	99 LEWIS POINT ROAD, FAIR HAVEN NJ 07704
Nachum Stein	director	QUADRAX CORP, 618 MAIN ST PO BOX 1001, WEST WARWICK RI 02893
Adam R. Levy	officer: CEO and President	2 AVENUE OF TWO RIVER SOUTH, RUMSON NJ 07760
Scott Robert Henry	director	34A ATLANTIC AVE., COHASSET MA 02025
David Stefansky	director	850 THIRD AVENUE, SUITE 1801, NEW YORK NY 10022
Yaakov Spinrad	director	3450 OAKTON ST, SKOKIE IL 60076
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Bezalel Partners Llc	10 percent owner	C/O KRIEGER & PRAGER LLP, 39 BROADWAY, STE 920, NEW YORK NY 10006
David Ian Johnson	director, officer: Chief Executive Officer	C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Adynxx, Inc.	10 percent owner	100 PINE ST., STE. 500, SAN FRANCISCO CA 94111